Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$8.03 -2.3%	$8.42	$3.63 ▼ $14.44	$685.54M	0.68	1.20 million shs	441,883 shs
EXAI Exscientia	$4.84	$4.97	$3.80 ▼ $6.49	$632.93M	0.83	663,980 shs	N/A
SANA Sana Biotechnology	$2.59 +2.0%	$1.96	$1.26 ▼ $7.40	$583.99M	1.78	3.55 million shs	2.48 million shs
VALN Valneva	$6.01 -2.3%	$6.46	$3.62 ▼ $8.66	$510.26M	1.81	42,636 shs	12,704 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	0.00%	-2.90%	-4.06%	-14.85%	+114.13%
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	-4.54%
SANA Sana Biotechnology	0.00%	-8.80%	+51.46%	-11.60%	-62.02%
VALN Valneva	0.00%	-2.26%	-2.59%	-11.62%	-28.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.8503 of 5 stars	3.7	0.0	4.7	3.5	0.8	0.6
EXAI Exscientia	0.2183 of 5 stars	1.0	0.0	0.0	0.6	1.7	0.6
SANA Sana Biotechnology	1.9411 of 5 stars	3.4	0.0	0.0	1.6	3.3	0.6
VALN Valneva	2.6396 of 5 stars	3.5	5.0	0.0	2.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	447.95% Upside
EXAI Exscientia	2.00	Hold	$5.00	3.31% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	316.99% Upside
VALN Valneva	3.00	Buy	$15.50	157.90% Upside

Current Analyst Ratings Breakdown

Latest AVXL, VALN, EXAI, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/15/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/9/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/31/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/31/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/24/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $15.00
3/21/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/18/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A
VALN Valneva	$186.06M	2.75	N/A	N/A	$2.00 per share	3.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	8/5/2025 (Estimated)
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
SANA Sana Biotechnology	-$283.26M	-$0.88	N/A	N/A	N/A	N/A	-84.22%	-44.97%	8/6/2025 (Estimated)
VALN Valneva	-$109.78M	-$1.19	N/A	N/A	N/A	-4.35%	-3.93%	-1.42%	8/12/2025 (Estimated)

Latest AVXL, VALN, EXAI, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/7/2025	Q1 2025	VALN Valneva	-$0.40	-$0.13	+$0.27	-$0.13	$41.80 million	$51.79 million
3/20/2025	Q4 2024	VALN Valneva	-$0.22	-$0.54	-$0.32	-$0.54	$55.64 million	$56.48 million
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
EXAI Exscientia	0.06	4.54	4.54
SANA Sana Biotechnology	N/A	4.47	4.47
VALN Valneva	0.70	2.78	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
EXAI Exscientia	41.58%
SANA Sana Biotechnology	88.23%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
EXAI Exscientia	16.40%
SANA Sana Biotechnology	30.10%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.71 million	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
SANA Sana Biotechnology	380	225.48 million	153.83 million	Optionable
VALN Valneva	700	85.09 million	69.15 million	Not Optionable

AVXL, VALN, EXAI, and SANA Headlines

Recent News About These Companies

Valneva SE (NASDAQ:VALN) Sees Large Drop in Short Interest

June 14 at 7:59 AM | marketbeat.com

Valneva (NASDAQ:VALN) Stock Price Down 4% - Here's What Happened

June 12 at 1:20 PM | marketbeat.com

Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure

June 10, 2025 | indiaeducationdiary.in

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

June 10, 2025 | reuters.com

Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children

June 10, 2025 | pharmexec.com

UK restricts use of Valneva chikungunya vaccine for safety review

June 10, 2025 | yahoo.com

UK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)

June 10, 2025 | msn.com

Valneva reports data from Phase II chikungunya vaccine trial in children

June 6, 2025 | finance.yahoo.com

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

June 5, 2025 | globenewswire.com

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

June 4, 2025 | globenewswire.com

Valneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?

June 3, 2025 | marketbeat.com

Valneva SE (NASDAQ:VALN) Sees Large Decrease in Short Interest

June 2, 2025 | marketbeat.com

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025 | globenewswire.com

US CDC accepts recommendations for chikungunya vaccines

May 21, 2025 | msn.com

London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine

May 19, 2025 | cbc.ca

US Advises Older Travelers to Avoid Chikungunya Vaccine

May 16, 2025 | infectiousdiseaseadvisor.com

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

May 15, 2025 | pharmexec.com

FDA, CDC recommend pause in Valneva chikungunya vaccine for older adults

May 14, 2025 | cidrap.umn.edu

U.S. Advises Older Travelers to Avoid Chikungunya Vaccine

May 13, 2025 | usnews.com

FDA warns seniors to avoid this vaccine after deadly complications

May 13, 2025 | msn.com

2VALN : US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For...

May 13, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, VALN, EXAI, and SANA Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$8.03 -0.19 (-2.31%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.96 -0.06 (-0.81%)

As of 06/13/2025 06:38 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Sana Biotechnology NASDAQ:SANA

$2.59 +0.05 (+1.97%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.58 0.00 (-0.19%)

As of 06/13/2025 07:15 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Valneva NASDAQ:VALN

$6.01 -0.14 (-2.28%)

As of 06/13/2025 04:00 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time